Kizoo Provides Seed Funding for Elastrin Therapeutics to Develop Groundbreaking New Technology Capable of Reversing Tissue and Organ Calcification
Kizoo Provides Seed Funding for Elastrin Therapeutics to Develop Groundbreaking New Technology Capable of Reversing Tissue and Organ Calcification
03/04/21, 12:49 PM
Location
berlinRound Type
seed
Elastrin is a biotechnology startup leveraging a platform technology to develop therapeutics that render calcified tissue and organs supple again. It is the latest addition to the growing portfolio of Kizoo Technology Capital, a rejuvenation biotech investor focused on reversing age-related damage on a cellular and molecular level. Elastrin’s lead asset is a nanoparticle conjugated with a novel monoclonal antibody for the treatment of heart valve and vascular calcification.
Company Info
Location
berlin, maryland, united states
Additional Info
Elastrin Therapeutics is a South Carolina-based biotech developing novel therapies to reverse cardiovascular disease. Its underlying technology was developed by Dr. Naren Vyavahare during the last 20 years at Clemson University, in collaboration with Dr. Charles Rice who developed the antibody. Our team built a proprietary platform that targets and restores degraded elastin by removing the harmful calcification that stiffens arteries. The platform significantly improves the efficacy of drugs and eliminates side effects by combining particle design with elastin targeting.